Sacituzumab Govitecan is named as an intervention in 33 current clinical trials in our USA, China, UK and Ireland registers. 12 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Gilead Sciences (16). The most-studied condition is Triple Negative Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Sacituzumab Govitecan on the HPRA medicines list.
No entry for Sacituzumab Govitecan in the EMA, FDA or German BfArM shortage lists we track.
| Condition (as registered) | Trials |
|---|---|
| Triple Negative Breast Cancer | 5 |
| Solid Tumor | 3 |
| HR+, HER2-, Advanced Breast Cancer | 2 |
| Metastatic Breast Cancer | 2 |
| HER2-negative Breast Cancer | 2 |
| Metastatic Urothelial Cancer | 1 |
| PD-L1 Positive | 1 |
| PD-L1 Negative | 1 |
| Non-small Cell Lung Cancer | 1 |
| Lung Cancer | 1 |
| Advanced or Metastatic Non-Small-Cell Lung Cancer | 1 |
| Resectable Non-Small-Cell Lung Cancer | 1 |
| Endometrial Cancer | 1 |
| Locally Advanced or Unresectable Metastatic Breast Cancer | 1 |
| Stage IV Breast Cancer | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Advanced Solid Tumor | 1 |
| HR+/HER2- Breast Cancer | 1 |
| CCNE1 Amplification | 1 |
| Metastatic Solid Tumor | 1 |
| Precision Medicine | 1 |
| Metastatic Triple-negative Breast Cancer | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 1 |
| Locally Advanced or Metastatic Urothelial Carcinoma | 1 |
| Advanced Solid Tumors | 1 |
| Triple Negative Locally Advanced Non-resectable Breast Cancer | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Leptomeningeal Metastases | 1 |
| Advanced Breast Cancer | 1 |
| Epithelial Ovarian Cancer | 1 |
| Fallopian Tube Cancers | 1 |
| Primary | 1 |
| Primary Peritoneal Carcinoma | 1 |
| TNBC | 1 |
| Oral Squamous Cell Carcinoma (OSCC) | 1 |
| Stage IV (Metastatic) Breast Cancer | 1 |
| Advanced or Metastatic Pancreatic Adenocarcinoma | 1 |
| Advanced or Metastatic Breast Cancer (BC) | 1 |
| Locally Advanced or Metastatic Breast Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Gilead Sciences | 16 |
| Avenzo Therapeutics, Inc. | 1 |
| Tianjin Medical University Second Hospital | 1 |
| GBG Forschungs GmbH | 1 |
| Hoffmann-La Roche | 1 |
| Merck Sharp & Dohme LLC | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| Marengo Therapeutics, Inc. | 1 |
| IDEAYA Biosciences | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Guangzhou Medical University | 1 |
| Guangdong Provincial People's Hospital | 1 |
| Shanghai Gynecologic Oncology Group | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Shanghai East Hospital | 1 |
+ 3 more sponsors in the trial list above.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 19 | 7 |
| Clinical trials in China | 19 | 6 |
| Clinical trials in UK | 13 | 3 |
| Clinical trials in Ireland | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
33 current trials in our USA, China, UK and Ireland registers name Sacituzumab Govitecan (also registered as RO7445735) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 12 of the 33 trials are recruiting: 7 with sites in USA, 6 with sites in China, 3 with sites in UK and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Gilead Sciences (16), Avenzo Therapeutics, Inc (1), Tianjin Medical University Second Hospital (1) and GBG Forschungs GmbH (1), among 18 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Sacituzumab Govitecan, for example Trodelvy 200 mg powder for concentrate for solution for infusion (Gilead Sciences Ireland UC). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Sacituzumab Govitecan has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Sacituzumab Govitecan works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sacituzumab Govitecan works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sacituzumab Govitecan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.